2024
Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study
Xu X, Ai L, Hu K, Liang L, Lv M, Wang Y, Cui Y, Li W, Li Q, Yu S, Feng Y, Liu Q, Yang Y, Zhang J, Xu F, Yu Y, Liu T. Tislelizumab plus cetuximab and irinotecan in refractory microsatellite stable and RAS wild-type metastatic colorectal cancer: a single-arm phase 2 study. Nature Communications 2024, 15: 7255. PMID: 39179622, PMCID: PMC11343749, DOI: 10.1038/s41467-024-51536-x.Peer-Reviewed Original ResearchConceptsMetastatic colorectal cancerVariant allele frequencyPhase 2 studyEpidermal growth factor receptorAdverse eventsRAS wild-type metastatic colorectal cancerRAS wt metastatic colorectal cancerSingle-arm phase 2 studyWild-type metastatic colorectal cancerColorectal cancerTreatment-related adverse eventsAnti-PD-1Disease control rateProgression-free survivalRAS wild-typeTumor immune responseCombined treatment regimenWild-typeGrowth factor receptorIrinotecan combinationOverall survivalAnti-EGFRPrimary endpointTumor DNASingle-armDeterministic reprogramming of neutrophils within tumors
Ng M, Kwok I, Tan L, Shi C, Cerezo-Wallis D, Tan Y, Leong K, Calvo G, Yang K, Zhang Y, Jin J, Liong K, Wu D, He R, Liu D, Teh Y, Bleriot C, Caronni N, Liu Z, Duan K, Narang V, Ballesteros I, Moalli F, Li M, Chen J, Liu Y, Liu L, Qi J, Liu Y, Jiang L, Shen B, Cheng H, Cheng T, Angeli V, Sharma A, Loh Y, Tey H, Chong S, Iannacone M, Ostuni R, Hidalgo A, Ginhoux F, Ng L. Deterministic reprogramming of neutrophils within tumors. Science 2024, 383: eadf6493. PMID: 38207030, PMCID: PMC11087151, DOI: 10.1126/science.adf6493.Peer-Reviewed Original Research
2023
Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial
Tian J, Chen J, Chao S, Pelka K, Giannakis M, Hess J, Burke K, Jorgji V, Sindurakar P, Braverman J, Mehta A, Oka T, Huang M, Lieb D, Spurrell M, Allen J, Abrams T, Clark J, Enzinger A, Enzinger P, Klempner S, McCleary N, Meyerhardt J, Ryan D, Yurgelun M, Kanter K, Van Seventer E, Baiev I, Chi G, Jarnagin J, Bradford W, Wong E, Michel A, Fetter I, Siravegna G, Gemma A, Sharpe A, Demehri S, Leary R, Campbell C, Yilmaz O, Getz G, Parikh A, Hacohen N, Corcoran R. Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. Nature Medicine 2023, 29: 458-466. PMID: 36702949, PMCID: PMC9941044, DOI: 10.1038/s41591-022-02181-8.Peer-Reviewed Original ResearchConceptsPrimary end pointColorectal cancerResponse rateEnd pointPD-1Immune responseSingle-arm phase 2 clinical trialMAPK inhibitionMEK inhibitionPhase 2 clinical trialTreatment tumor biopsiesDisease control rateSecondary end pointsPhase 2 trialProgression-free survivalBetter clinical outcomesDuration of responseOverall response rateTumor immune responseFurther clinical evaluationTumor cell-intrinsic mechanismsMAPK pathway inhibitionPatient-derived organoidsCell-intrinsic mechanismsOverall survival
2018
Tumour-immune dynamics with an immune checkpoint inhibitor
Nikolopoulou E, Johnson L, Harris D, Nagy J, Stites E, Kuang Y. Tumour-immune dynamics with an immune checkpoint inhibitor. Letters In Biomathematics 2018, 5: s137-s159. DOI: 10.1080/23737867.2018.1440978.Peer-Reviewed Original ResearchProteins programmed death-1Anti-PD-1Immune checkpoint inhibitorsTumor-immune dynamicsCheckpoint inhibitorsAnti-PD-1 drugsLigand PD-L1Eradicate tumor cellsTumor immune responseFunctional immune systemAntitumour responseDeath-1PD-L1Tumor-freeControl tumorsTumor equilibriumTumor cellsClinical trialsContinuous treatmentImmune systemTreatmentTumor-immune modelInhibitorsTumorTherapy
2017
The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system
Yang C, Cheng H, Luo G, Lu Y, Guo M, Jin K, Wang Z, Yu X, Liu C. The metastasis status and tumor burden-associated CA125 level combined with the CD4/CD8 ratio predicts the prognosis of patients with advanced pancreatic cancer: A new scoring system. European Journal Of Surgical Oncology 2017, 43: 2112-2118. PMID: 28802662, DOI: 10.1016/j.ejso.2017.07.010.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCA-125 AntigenCarcinoma, Pancreatic DuctalCD4 Lymphocyte CountCD8-Positive T-LymphocytesFemaleFlow CytometryHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm StagingPancreatic NeoplasmsPredictive Value of TestsPrognosisRetrospective StudiesSurvival RateTumor BurdenConceptsCD4/CD8 ratioNew scoring systemAdvanced pancreatic cancerCD8 ratioPrognosis of patientsCA125 levelsPancreatic cancerScoring systemPrognostic valueHigher CD4/CD8 ratioMultivariate analysisAdvanced pancreatic cancer patientsComplete clinical dataHigher CA125 levelsKaplan-Meier methodIndependent prognostic factorPancreatic cancer patientsLog-rank testTumor immune responseCox hazard modelPrognostic factorsCancer patientsMetastasis statusClinical dataImmune response
2012
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
Park J, Wrzesinski SH, Stern E, Look M, Criscione J, Ragheb R, Jay SM, Demento SL, Agawu A, Licona Limon P, Ferrandino AF, Gonzalez D, Habermann A, Flavell RA, Fahmy TM. Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. Nature Materials 2012, 11: 895-905. PMID: 22797827, PMCID: PMC3601683, DOI: 10.1038/nmat3355.Peer-Reviewed Original ResearchConceptsInterleukin-2TGF-β inhibitorTumor microenvironmentImmune responseLocal tumor immune responseMultiple immunologic mechanismsT cell infiltrationNatural killer cellsTumor immune responseAdaptive immune responsesTumor-bearing miceImmunotherapy resultsConventional immunotherapyImmunologic mechanismsKiller cellsTumor immunotherapyMetastatic melanomaConventional cytokinesProtein cytokinesHigh dosesTumor growthGrowth factorMolecular inhibitorsCombination deliveryImmunotherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply